Treatment of non-small cell lung cancer with CT guided percutaneous cisplatin sustained release tumor implantation
Objective To investigate and analyze the efficacy of CT guided percutaneous cisplatin cisplatin implantation in the treatment of non-small cell lung cancer.Methods 80 cases of non small cell lung cancer patients in our hospital from January 2015 to March 2016 were randomly divided into the control group and the experimental group, each group of 40 patients.The control group was treated with cisplatin and cisplatin, and the patients in the experimental group were treated with CT guided percutaneous cisplatin sustained-release implantation.The clinical standards of the experimental group and the control group were compared and analyzed.Results After treatment, the number of invalid cases in the experimental group was 8 cases, the effective number was 32 cases, the effective rate was 80%.The number of invalid cases in the control group was 32 cases, and the effective number was 8 cases.The effective rate of the patients in the experimental group was significantly higher than that in the control group (P<0.05).The 1-year survival rate of the experimental group was 77.5%, significantly higher than that of the control group, and the survival rate was 60%, with statistical difference (P<0.05).The incidence of adverse reactions in the experimental group (37.5%) was significantly lower than that in the control group (17.5%), with statistical difference (P<0.05).Conclusion CT guided percutaneous treatment of percutaneous intratumoral implantation of slow-release cisplatin in treatment of non-small cell lung cancer can improve the treatment efficiency in a certain degree, high security, with the further promotion and application significance.
CT guided percutaneous delayed release cisplatinimplantation therapynon-small cell lung cancer
NETL
NSTL
万方数据
维普
